Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Cited by (1,077)

Items 501–600 of 1,077

1. Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs
   Adrian Whitty, Mengqi Zhong, Lauren A. Viarengo‐Baker, Dmitri Beglov, David R. Hall, Sándor Vajda · 2016 · Drug Discovery Today
2. Features of protein–protein interactions that translate into potent inhibitors: topology, surface area and affinity
   Matthew C. P. Smith, Jason E. Gestwicki · 2012 · Expert Reviews in Molecular Medicine
3. On the nature of cavities on protein surfaces: Application to the identification of drug‐binding sites
   Murad Nayal, Barry H. Honig · 2006 · Proteins Structure Function and Bioinformatics
4. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes
   Þorsteinn Loftsson, Marcus Eli Brewster · 2011 · Journal of Pharmacy and Pharmacology
5. Novel Chemical Space Exploration via Natural Products
   Josefin Rosén, Johan Gottfries, Sorel Mureşan, Anders Backlund, Tudor Ionel Oprea · 2009 · Journal of Medicinal Chemistry
6. Drugs as materials: valuing physical form in drug discovery
   Colin R. Gardner, Christopher T. Walsh, Örn Almarsson · 2004 · Nature Reviews Drug Discovery
7. Quantitative structure-activity relationship methods: Perspectives on drug discovery and toxicology
   Roger Perkins, Hong Fang, Weida Tong, William Jeffrey Welsh · 2003 · Environmental Toxicology and Chemistry
8. Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs
   Aziz Maleki, Hélène Kettiger, Aurélie Schoubben, Jessica M. Rosenholm, Valeria Ambrogi, Mehrdad Hamidi · 2017 · Journal of Controlled Release
9. Chemical modification: the key to clinical application of RNA interference?
   David R. Corey · 2007 · Journal of Clinical Investigation
10. Cocrystals of Hydrochlorothiazide: Solubility and Diffusion/Permeability Enhancements through Drug–Coformer Interactions
    Palash Sanphui, Vemula Kusum Devi, Deepa Clara, Nidhi Malviya, Somnath Ganguly, Gautam Radhakrishna Desiraju · 2015 · Molecular Pharmaceutics
11. Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
    Ronald Domalaon, Temilolu Idowu, George G. Zhanel, Frank Schweizer · 2018 · Clinical Microbiology Reviews
12. The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication
    Rask-Andersen, Mathias, Masuram, Surendar, Schiöth, Helgi B. · 2014 · Annual Review of Pharmacology and Toxicology
13. Diversity-oriented synthesis; a spectrum of approaches and results
    Richard J. Spandl, Andreas Bender, David R. Spring · 2008 · Organic & Biomolecular Chemistry
14. Predicting ADME properties in silico: methods and models
    Darko Butina, Matthew Segall, Katrina E. Frankcombe · 2002 · Drug Discovery Today
15. Oxidative Stress and Antioxidants—A Critical Review on In Vitro Antioxidant Assays
    Raghavendhar R. Kotha, Fakir Shahidullah Tareq, Elif Yıldız, Devanand L. Luthria · 2022 · Antioxidants
16. Profiling drug-like properties in discovery research
    Li Di, Edward H. Kerns · 2003 · Current Opinion in Chemical Biology
17. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv
    Subramaniam Ananthan, Ellen R. Faaleolea, Robert C. Goldman, Judith Varady Hobrath, Cecil D. Kwong, Barbara E. Laughon, Joseph A. Maddry, Alka Mehta, Lynn A. Rasmussen, Robert C. Reynolds et al. · 2009 · Tuberculosis
18. Assessing drug-likeness – what are we missing?
    Giulio Vistoli, Alessandro Pedretti, Bernard Testa · 2008 · Drug Discovery Today
19. Transdermal drug delivery: 30 + years of war and still fighting!
    Sandra Wiedersberg, Richard H. Guy · 2014 · Journal of Controlled Release
20. When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis
    Scannell, Jack W., Bosley, Jim · 2016 · PLOS ONE
21. Prospects for productivity
    Bruce L Booth, Rodney W. Zemmel · 2004 · Nature Reviews Drug Discovery
22. FAF-Drugs3: a web server for compound property calculation and chemical library design
    David Lagorce, Olivier Spérandio, Jonathan B. Baell, Maria A. Miteva, Bruno O. Villoutreix · 2015 · Nucleic Acids Research
23. Can cell systems biology rescue drug discovery?
    Eugene C. Butcher · 2005 · Nature Reviews Drug Discovery
24. The structural modification of natural products for novel drug discovery
    Hong Yao, Junkai Liu, Shengtao Xu, Zheying Zhu, Jinyi Xu · 2016 · Expert Opinion on Drug Discovery
25. Natural products as a robust source of new drugs and drug leads: Past successes and present day issues
    Rishton, Gilbert M. · 2008 · The American Journal of Cardiology
26. Cell culture-based models for intestinal permeability: A critique
    Praveen V. Balimane, Saeho Chong · 2005 · Drug Discovery Today
27. Screening in a spirit haunted world
    Brian K. Shoichet · 2006 · Drug Discovery Today
28. Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors
    David Lagorce, Dominique Douguet, Maria A. Miteva, Bruno O. Villoutreix · 2017 · Scientific Reports
29. Late-stage Functionalization for Improving Drug-like Molecular Properties
    Nathan J. Castellino, Andrew P. Montgomery, Jonathan J. Danon, Michael Kassiou · 2023 · Chemical Reviews
30. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery
    Jasna Fejzo, Christopher A. Lepre, Jeffrey W. Peng, Guy W. Bemis, Ajay, Mark A. Murcko, Jonathan M. Moore · 1999 · Chemistry & Biology
31. Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target
    Ye, Shiming, Huang, Yadong, Müllendorff, Karin, Dong, Liming, Giedt, Gretchen, Meng, Elaine C., Cohen, Fred E., Kuntz, Irwin D., Weisgraber, Karl H., Mahley, Robert W. · 2005 · Proceedings of the National Academy of Sciences
32. The Concept of an Ideal Antibiotic: Implications for Drug Design
    Márió Gajdács · 2019 · Molecules
33. Designing antibodies as therapeutics
    Paul J. Carter, Arvind Rajpal · 2022 · Cell
34. Chemical Space of DNA-Encoded Libraries
    Raphael M. Franzini, Cassie Randolph · 2016 · Journal of Medicinal Chemistry
35. Progress in predicting human ADME parameters in silico
    Sean Ekins, Chris L. Waller, Peter W. Swaan, Gabriele Cruciani, Steven A. Wrighton, James H. Wikel · 2000 · Journal of Pharmacological and Toxicological Methods
36. Soluble Extract from Moringa oleifera Leaves with a New Anticancer Activity
    Il Lae Jung · 2014 · PLoS ONE
37. Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents
    J.A. Hernandez Prada, Anderson Jose Ferreira, Michael J. Katovich, Vinayak Shenoy, Yanfei Qi, Robson A.S. Santos, Ronald K. Castellano, Andrew J. Lampkins, Vladimir Gubala, David A. Ostrov et al. · 2008 · Hypertension
38. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
    Ann D. Kwong, Robert S. Kauffman, Patricia N. Hurter, Peter Mueller · 2011 · Nature Biotechnology
39. Current status and future prospects of nanotechnology in cosmetics
    Albert Mihranyan, Natália Ferraz, Maria Strømme · 2011 · Progress in Materials Science
40. Ordered Mesoporous Silica Material SBA-15: A Broad-Spectrum Formulation Platform for Poorly Soluble Drugs
    Michiel Van Speybroeck, Valéry Barillaro, Thao Do Thi, Randy Mellaerts, Johan A. Martens, Jan Van Humbeeck, Jan Vermant, Pieter Annaert, Guy Van den Mooter, Patrick Augustijns · 2008 · Journal of Pharmaceutical Sciences
41. Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders
    C. Heidbreder, A. H. Newman · 2010 · Annals of the New York Academy of Sciences
42. Pathways for Small Molecule Delivery to the Central Nervous System across the Blood-Brain Barrier
    John L. Mikitsh, Ann‐Marie Chacko · 2014 · Perspectives in Medicinal Chemistry
43. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
    Shanique B. Alabi, Craig M. Crews · 2021 · Journal of Biological Chemistry
44. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information
    Hong Jun Yang, Qin Chu, Yinghong Li, Lin Tao, Jin Zhou, Chun Yan Yu, Feng Xu, Zhe Chen, Feng Zhu, Yu Chen · 2015 · Nucleic Acids Research
45. The Light and Dark Sides of Virtual Screening: What Is There to Know?
    Aleix Gimeno, María José Ojeda, Sarah Tomas‐Hernández, Adrià Cereto‐Massagué, Raúl Beltrán‐Debón, Miquel Mulero, Gerard Pujadas, Santiago Garcı́a-Vallvé · 2019 · International Journal of Molecular Sciences
46. Challenges in Modern Drug Discovery: A Case Study of Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
    F. George Njoroge, Kevin X. Chen, Neng‐Yang Shih, John J. Piwinski · 2008 · Accounts of Chemical Research
47. Predictive in silico modeling for hERG channel blockers
    Alex M. Aronov · 2005 · Drug Discovery Today
48. Sanjeevini: a freely accessible web-server for target directed lead molecule discovery
    Bhyravabhotla Jayaram, Tanya Singh, Goutam Mukherjee, Abhinav Mathur, Shashank Shekhar, Vandana Shekhar · 2012 · BMC Bioinformatics
49. A small-molecule screen in C. elegans yields a new calcium channel antagonist
    Trevor C. Y. Kwok, Nicole Ricker, Regina Fraser, Allen W. Chan, Andrew R. Burns, Elise F. Stanley, Peter McCourt, Sean R. Cutler, Peter John Roy · 2006 · Nature
50. Quantitative Analysis of Molecular Absorption into PDMS Microfluidic Channels
    Jack D. Wang, Nicholas J. Douville, Shuichi Takayama, Mohamed E. H. ElSayed · 2012 · Annals of Biomedical Engineering
51. N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion
    Shibo Jiang, Hong Lü, Shuwen Liu, Qian Zhao, Yuxian He, Asim Kumar Debnath · 2004 · Antimicrobial Agents and Chemotherapy
52. Bioavailability issues in studying the health effects of plant polyphenolic compounds
    Chung Shu Yang, Shengmin Sang, Joshua D. Lambert, Mao‐Jung Lee · 2008 · Molecular Nutrition & Food Research
53. Break on through to the Other Side—Biophysics and Cell Biology Shed Light on Cell‐Penetrating Peptides
    Rainer Fischer, Mariola Fotin‐Mleczek, Hansjörg Hufnagel, Roland E. Brock · 2005 · ChemBioChem
54. Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy
    Xiang Ling, Jiasheng Tu, Junqing Wang, Aram Shajii, Na Kong, Chan Feng, Ye Zhang, Mikyung Yu, Tian Xie, Zameer Bharwani et al. · 2018 · ACS Nano
55. FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects
    David Lagorce, Olivier Spérandio, Hervé Galons, Maria A. Miteva, Bruno O. Villoutreix · 2008 · BMC Bioinformatics
56. Chemogenomic approaches to rational drug design
    Didier Rognan · 2007 · British Journal of Pharmacology
57. Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity
    Choi, Jung-Suk, Braymer, Joseph J., Nanga, Ravi P. R., Ramamoorthy, Ayyalusamy, Lim, Mi Hee · 2010 · Proceedings of the National Academy of Sciences
58. New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery
    Alejandro Sosnik, Angel Montero Carcaboso, Romina Julieta Glisoni, Marcela Analia Moretton, Diego A. Chiappetta · 2009 · Advanced Drug Delivery Reviews
59. Fluorescence Spectroscopic Profiling of Compound Libraries
    Anton M. Simeonov, Ajit Jadhav, Craig J. Thomas, Yuhong Wang, Ruili Huang, Noel T Southall, Paul Shinn, Jeremy A. Smith, Christopher P. Austin, Douglas S. Auld et al. · 2008 · Journal of Medicinal Chemistry
60. BitterDB: a database of bitter compounds
    Ayana Dagan‐Wiener, Marina Shudler, Anat Levit, Masha Y. Niv · 2011 · Nucleic Acids Research
61. Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
    David J. Brayden, Timothy A. Hill, David P. Fairlie, Sam Maher, Randall J. Mrsny · 2020 · Advanced Drug Delivery Reviews
62. Targeted and multifunctional arene ruthenium chemotherapeutics
    Gregory Stuart Smith, Bruno Therrien · 2011 · Dalton Transactions
63. Inhibition of protein–protein interactions using designed molecules
    Andrew John Wilson · 2009 · Chemical Society Reviews
64. Artemisone—A Highly Active Antimalarial Drug of the Artemisinin Class
    Richard Kingston Haynes, Burkhard Fugmann, Jörg Stetter, Karl H. Rieckmann, Hans‐Dietrich Heilmann, Ho‐Wai Chan, Man‐Ki Cheung, William W.‐L. Lam, Ho Ning Wong, Simon L. Croft et al. · 2006 · Angewandte Chemie International Edition
65. A review of the pharmaceutical exposome in aquatic fauna
    Thomas H. Miller, Nicolas R. Bury, Stewart F. Owen, James I. MacRae, Leon Barron · 2018 · Environmental Pollution
66. Structural Simplification of Natural Products
    Shengzheng Wang, Guoqiang Dong, Chunquan Sheng · 2019 · Chemical Reviews
67. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs
    Kohsaku Kawakami · 2012 · Advanced Drug Delivery Reviews
68. Multispecific drugs herald a new era of biopharmaceutical innovation
    Raymond J. Deshaies · 2020 · Nature
69. Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches
    David Dahlgren, Hans Lennernäs · 2019 · Pharmaceutics
70. A Perspective on Multi-target Drugs for Alzheimer’s Disease
    Benek, Ondrej, Korabecny, Jan, Soukup, Ondrej · 2020 · Trends in Pharmacological Sciences
71. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity
    Alan P. Hill, Robert J. Young · 2010 · Drug Discovery Today
72. Strong and weak hydrogen bonds in the protein–ligand interface
    Sunil K. Panigrahi, Gautam Radhakrishna Desiraju · 2007 · Proteins Structure Function and Bioinformatics
73. De novo branching cascades for structural and functional diversity in small molecules
    M. García-Castro, Lea Kremer, Christopher D. Reinkemeier, Christian Unkelbach, Carsten Strohmann B, Slava Ziegler, Claude Ostermann, Kamal Kumar · 2015 · Nature Communications
74. ElogP oct : A Tool for Lipophilicity Determination in Drug Discovery
    Franco Lombardo, Marina Y. Shalaeva, Karl A. Tupper, Feng Gao, Michael H. Abraham · 2000 · Journal of Medicinal Chemistry
75. Ligand efficiency as a guide in fragment hit selection and optimization
    Sabine Schultes, Chris de Graaf, Eric E. J. Haaksma, Iwan J. P. de Esch, Rob Leurs, Oliver Krämer · 2010 · Drug Discovery Today Technologies
76. Pharmaceutical Cocrystals: New Solid Phase Modification Approaches for the Formulation of APIs
    Anna Karagianni, Maria Malamatari, Kyriakos Kachrimanis · 2018 · Pharmaceutics
77. pH-Metric Solubility. 2: Correlation Between the Acid-Base Titration and the Saturation Shake-Flask Solubility-pH Methods
    Alex Avdeef, Cynthia M. Berger, Charles R. Brownell · 2000 · Pharmaceutical Research
78. Flavonoid interactions during digestion, absorption, distribution and metabolism: a sequential structure–activity/property relationship-based approach in the study of bioavailability and bioactivity
    Gerard Bryan Gonzales, Guy J. Smagghe, Charlotte Grootaert, Moisés João Zotti, Katleen Raes, John Van Camp · 2015 · Drug Metabolism Reviews
79. A Win–Win Solution in Oral Delivery of Lipophilic Drugs: Supersaturation via Amorphous Solid Dispersions Increases Apparent Solubility without Sacrifice of Intestinal Membrane Permeability
    Jonathan M. Miller, Avital Beig, Robert A. Carr, Julie K. Spence, Arik Dahan · 2012 · Molecular Pharmaceutics
80. Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs
    Christel A. S. Bergström, René Holm, Søren Astrup Jørgensen, Sara B. E. Andersson, Per Artursson, Stefania Beato, Anders Borde, Karl J. Box, Marcus Eli Brewster, Jennifer Dressman et al. · 2013 · European Journal of Pharmaceutical Sciences
81. Discovery of Inhibitors that Elucidate the Role of UCH-L1 Activity in the H1299 Lung Cancer Cell Line
    Yichin Liu, Hilal Ahmed Lashuel, Sungwoon Choi, Xuechao Xing, April W. Case, Jake Ni, Li-An Yeh, Gregory D. Cuny, Ross L. Stein, Peter T. Lansbury · 2003 · Chemistry & Biology
82. Virtual drug discovery and development for neglected diseases through public–private partnerships
    Solomon Nwaka, Robert G. Ridley · 2003 · Nature Reviews Drug Discovery
83. Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations
    Letchford, Kevin, Liggins, Richard, Burt, Helen · 2008 · Journal of Pharmaceutical Sciences
84. Pharmaceuticals that contain polycyclic hydrocarbon scaffolds
    Tegan P. Stockdale, Craig M. Williams · 2015 · Chemical Society Reviews
85. The graphical representation of ADME-related molecule properties for medicinal chemists
    Timothy J. Ritchie, Peter Ertl, Richard A. Lewis · 2010 · Drug Discovery Today
86. Current industrial practices of assessing permeability and P-glycoprotein interaction
    Praveen V. Balimane, Yong–Hae Han, Saeho Chong · 2006 · The AAPS Journal
87. Hit discovery and hit-to-lead approaches
    György Miklós Keserű, Gergely M. Makara · 2006 · Drug Discovery Today
88. Separation methods for estimating octanol–water partition coefficients
    Salwa K. Poole, Colin F. Poole · 2003 · Journal of Chromatography B
89. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis
    James C. Sacchettini, Eric J. Rubin, Joel S. Freundlich · 2007 · Nature Reviews Microbiology
90. Systemic Availability and Lymphatic Transport of Human Growth Hormone Administered by Subcutaneous Injection
    Susan A. Charman, Alicia M. Segrave, Glenn Anthony Edwards, Christopher J. H. Porter · 2000 · Journal of Pharmaceutical Sciences
91. Copper-related diseases: From chemistry to molecular pathology
    Guido Crisponi, Valeria Marina Nurchi, Daniela Fanni, Clara Gerosa, Sonia Nemolato, Gavino Faa · 2009 · Coordination Chemistry Reviews
92. DOGS: Reaction-Driven de novo Design of Bioactive Compounds
    Hartenfeller, Markus, Zettl, Heiko, Walter, Miriam, Rupp, Matthias, Reisen, Felix, Proschak, Ewgenij, Weggen, Sascha, Stark, Holger, Schneider, Gisbert · 2012 · PLoS Computational Biology
93. Integrating virtual screening in lead discovery
    Tudor Ionel Oprea, Hans Matter · 2004 · Current Opinion in Chemical Biology
94. Systems Pharmacology for Investigation of the Mechanisms of Action of Traditional Chinese Medicine in Drug Discovery
    Wenjuan Zhang, Ying Huai, Zhiping Miao, Airong Qian, Yonghua Wang · 2019 · Frontiers in Pharmacology
95. Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Huai Hua San Against Ulcerative Colitis
    Jiaqin Liu, Jian Liu, Xiaoliang Tong, Weijun Peng, Shanshan Wei, Taoli Sun, Yikun Wang, Bikui Zhang, Wenqun Li · 2021 · Drug Design Development and Therapy
96. Protein-Ligand Docking in the New Millennium – A Retrospective of 10 Years in the Field
    Sérgio Filipe Sousa, António J. M. Ribeiro, João T. S. Coimbra, Rui P. P. Neves, Sílvia A. Martins, N. S. Hari Narayana Moorthy, Pedro Alexandrino Fernandes, Maria João Ramos · 2013 · Current Medicinal Chemistry
97. Natural phytochemicals and probiotics as bioactive ingredients for functional foods: Extraction, biochemistry and protected-delivery technologies
    Beatriz Vieira da Silva, João C.M. Barreira, M. Beatriz P.P. Oliveira · 2016 · Trends in Food Science & Technology
98. Metal complexes for therapeutic applications
    Johannes Karges, Ryjul W. Stokes, Seth M. Cohen · 2021 · Trends in Chemistry
99. Blood–Brain Barrier in Brain Tumors: Biology and Clinical Relevance
    Francesca Mo, Alessia Pellerino, Riccardo Soffietti, Roberta Rudà · 2021 · International Journal of Molecular Sciences
100. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective
     Andy Pike, Beth Williamson, Stephanie Harlfinger, Scott W. Martin, Dermot F. McGinnity · 2020 · Drug Discovery Today